Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: Clinical, immunologic, and virologic responses

Clinical Infectious Diseases

Volumn 34, Issue 6, 2002, Pages 813-821

  Tasker, Sybil A ^a   Wallace, Mark R ^a   Rubins, Jeffrey B ^c   Paxton, William B ^b,d   O'Brien, James ^c   Janoff, Edward N ^c  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; SKIN MANIFESTATION; STREPTOCOCCUS INFECTION;

ADULT; ANTIBODY FORMATION; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNIZATION; MALE; PNEUMOCOCCAL VACCINES; RNA, VIRAL;

EID: 0037087201     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/339044     Document Type: Article

References (57)

1. Pneumococcal disease during HIV infection - Epidemiologic, clinical, and immunologic perspectives
2. Pneumococcal bacteremia with pneumonia: Mortality in acquired immunodeficiency syndrome
3. The role of human immunodeficiency virus in pneumococcal bacteremia in San Francisco residents
4. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population
5. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California
6. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
7. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1
8. Response of recent HIV-seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine
9. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men
10. + lymphocytes
11. Safety of revaccination with pneumococcal polysaccharide vaccine
12. Human immunodeficiency virus-type I replication can be increased in peripheral blood of seropositive patients after influenza vaccination
13. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1
14. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine
15. Assessments of plasma HIV RNA and CD4 cell counts after combined pneumovax and tetanus toxoid vaccination: No detectable increase in replication 6 weeks after immunization
16. Effect of influenza vaccination in HIV-infected adults: A double-blind, placebo-controlled trial
17. Immune activation and virologic response to immunization in recent HIV type 1 seroconverters
18. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients
19. An analytical model applied to a multicenter pneumonoccal enzyme-linked immunosorbent assay study
20. Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal infection with encapsulated pneumococci
21. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: Determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide
22. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?
23. Role of cell wall polysaccharide in the assessment of IgG antibodies to the capsular polysaccharides of Streptococcus pneumoniae in childhood
24. Antibodies to pneumococcal capsular polysaccharides in children with human immunodeficiency virus infection given polyvalent pneumococcal vaccine
25. Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine
26. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection
27. Revaccination with pneumococcal vaccine of elderly persons six years after primary vaccination
28. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
29. Side effects associated with pneumococcal vaccination
30. Vaccination and HIV-1 replication during highly active antiretroviral therapy
31. The effects of immunization in human immunodeficiency virus type 1 infection
32. Activation of virus replication after vaccination of HIV-1-infected individuals
33. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex workers in Nairobi, Kenya
34. Invasive pneumococcal disease in the immunocompromised host
35. The changing epidemiology of pneumococcal bacteremia in human immunodeficiency virus infection
36. Pneumococcal vaccination and the incidence of pneumonia among HIV-1-infected persons
37. Pneumonia in HIV-infected patients: A case-control study of factors involved in risk and prevention
38. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients
39. Pneumococcal disease among human immunodeficiency virus-infected persons: Incidence, risk factors, and impact of vaccination
40. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients
41. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: Double-blind, randomised and placebo controlled study
42. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons
43. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly
44. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine
45. Induction of immunologic memory by conjugated vs. plain meningococcal C polysaccharide vaccine in toddlers: A randomized controlled trial
46. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses
47. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine
48. Antibody to capsular polysaccharides of Streptococcus pneumoniae: Prevalence, persistence, and response to revaccination
49. The epidemiology of invasive pneumococcal disease in Alaska, 1986-90: Ethnic differences and opportunities for prevention
50. A B cell superantigen-induced persistent "hole" in the B-1 repertoire
51. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: Results from a randomized trial
52. Sequential HIV RNA levels in patients with disseminated M. avium complex (MAC): A case control study
53. Bacterial pneumonia in persons infected with the human immunodeficiency virus
54. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome
55. Cigarette smoking and invasive pneumococcal disease
56. Highly active antiretroviral therapy decreases the incidence of bacteremia in human immunodeficiency virus-infected individuals
57. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection